Hoi-Kei Lon
Overview
Explore the profile of Hoi-Kei Lon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Conte U, Irby D, et al.
Target Oncol
. 2025 Feb;
PMID: 40000533
Background: Elranatamab is a BCMA-CD3 bispecific antibody approved for the treatment of relapsed or refractory multiple myeloma. Cytokine release syndrome is one of the most common adverse events associated with...
2.
Soltantabar P, Sharma S, Wang D, Lon H, Czibere A, Hickmann A, et al.
Clin Pharmacol Ther
. 2024 Mar;
115(6):1258-1268.
PMID: 38459622
B-cell maturation antigen (BCMA)-targeting immunotherapies (e.g., chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAbs)) have achieved remarkable clinical responses in patients with relapsed and/or refractory multiple myeloma (RRMM)....
3.
Hanafin P, Murthy A, Marathe D, Diep J, Krishnatry A, Lon H, et al.
J Pharmacokinet Pharmacodyn
. 2023 Jul;
50(4):243-250.
PMID: 37480411
The International Society of Pharmacometrics (ISoP) Mentorship Program (IMP) aims to help professionals at all career stages to transition into the pharmacometrics field, move to a different role/area within pharmacometrics,...
4.
Soltantabar P, Lon H, Parivar K, Wang D, Elmeliegy M
Crit Rev Oncol Hematol
. 2023 Jan;
182:103913.
PMID: 36681205
Oncology therapies shifted from chemotherapy to molecularly targeted agents and finally to the era of immune-oncology agents. In contrast to cytotoxic agents, molecularly targeted agents are more selective, exhibit a...
5.
Hoglinger G, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, et al.
Lancet Neurol
. 2021 Feb;
20(3):182-192.
PMID: 33609476
Background: Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the...
6.
Lon H, Cheng L, Nudurupati S, Loebbert R, Duan R, Kalabic J, et al.
Clin Ther
. 2021 Feb;
43(3):629-636.
PMID: 33549311
Purpose: Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that inhibits the p19 subunit of interleukin 23 from interacting with its receptor for the treatment of moderate to severe plaque...
7.
Wang J, Lon H, Lee S, Burckart G, Pisetsky D
Ther Innov Regul Sci
. 2018 Sep;
49(6):861-868.
PMID: 30222372
The field of oligonucleotide (OGN)-based therapeutics has been growing dramatically in the past decade, providing innovative platforms to develop agents for the treatment of a wide variety of clinical conditions....
8.
Lon H, Mendonca N, Goss S, Othman A, Locke C, Jin Z, et al.
Clin Pharmacol Drug Dev
. 2018 Jul;
8(3):290-303.
PMID: 30052328
Alicapistat is an orally active selective inhibitor of calpain 1 and 2 whose overactivation has been linked to Alzheimer disease (AD). Three studies were conducted in healthy subjects (18-55 years),...
9.
Lon H, DuBois D, Earp J, Almon R, Jusko W
Pharmacol Res Perspect
. 2015 Oct;
3(5):e00169.
PMID: 26516581
A mechanism-based model was developed to characterize the crosstalk between proinflammatory cytokines, bone remodeling biomarkers, and bone mineral density (BMD) in collagen-induced arthritic (CIA) rats. Male Lewis rats were divided...
10.
Lon H, Liu D, DuBois D, Almon R, Jusko W
J Pharmacokinet Pharmacodyn
. 2013 Nov;
40(6):701-12.
PMID: 24233383
The PK/PD of abatacept, a selective T cell co-stimulation modulator, was examined in rats with collagen-induced arthritis (CIA) using a nonlinear mixed effect modeling approach. Male Lewis rats underwent collagen...